Recursion Pharmaceuticals Stock News
$4.53
0.33%
yesterday
Nasdaq,
May 20, 09:49 pm CET
Recursion Pharmaceuticals Stock News
Positive
The Motley Fool
●
9 days ago
Artificial intelligence (AI) has taken over Wall Street. The leaders in this rapidly growing field are attracting significant attention.
Positive
The Motley Fool
●
10 days ago
The artificial intelligence (AI) revolution is reshaping our world at an unprecedented pace. As AI technology evolves, it's set to fundamentally transform countless industries through enhanced automation, operational efficiency, and dramatic improvements in workforce productivity.
Negative
The Motley Fool
●
12 days ago
Shares of Recursion Pharmaceuticals (RXRX -1.48%) fell this week. The stock lost 24% as of market close on Friday.
Negative
The Motley Fool
●
15 days ago
Shares of Recursion Pharmaceuticals (RXRX -11.15%) are tumbling on Tuesday. The stock lost 10.3% as of 2:50 p.m.
Neutral
GlobeNewsWire
●
15 days ago
Salt Lake City, May 06, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Bank of America 2025 Health Care Conference — Tuesday, May 13, 2025 JP Morgan Global Technology, Media and Communications Conference — Thursday, May 15, 2...
Negative
The Motley Fool
●
16 days ago
Recursion Pharmaceuticals (RXRX -15.53%) didn't have a fine start to the working week on Monday, at least as far as its stock was concerned. Investors traded out of it following the clinical-stage biotech's first-quarter earnings release and business update, and the share price was down by 15% in mid-session trading.
Neutral
Seeking Alpha
●
16 days ago
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Q1 2025 Results Conference Call May 5, 2025 8:00 AM ET Company Participants Chris Gibson - Co-Founder & Chief Executive Officer Najat Khan - Chief R&D Officer and Chief Commercial Officer Ben Taylor - Chief Financial Officer Chris Gibson Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion, and I'm delighted to welcome you to our...
Neutral
GlobeNewsWire
●
16 days ago
SALT LAKE CITY, May 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its first quarter ended March 31, 2025.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
